Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M B Atkins

Showing results (31-40 of 101) with videos related to

Pageof 11
Sort By:
Pathology and Immunopathology Research|January 1, 1988
Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cellsJ W Mier, F R Aronson, R P Numerof, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684B E Hillner, J M Kirkwood, M B Atkins, et al.
Critical Care Medicine|November 1, 1995
Effects of malignancy and interleukin-2 infusion on gut macromolecular permeabilityC M Ryan, M B Atkins, J W Mier, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1993
Possible myocardial toxicity associated with interleukin-4 therapyE G Trehu, J M Isner, J W Mier, et al.
Annals of Internal Medicine|April 15, 1993
Symptomatic exacerbation of Crohn disease after treatment with high-dose interleukin-2J A Sparano, L J Brandt, J P Dutcher, et al.
Diseases of the Colon and Rectum|April 1, 1994
Local excision of rectal carcinoma. Early results with combined chemoradiation therapy using 5-fluorouracil and leucovorinR A Graham, M B Atkins, D D Karp, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 15, 1987
Regulation of hepatic acute phase protein synthesis by products of interleukin 2 (IL 2)-stimulated human peripheral blood mononuclear cellsJ W Mier, C A Dinarello, M B Atkins, et al.
Annals of Internal Medicine|January 15, 1990
Nosocomial sepsis associated with interleukin-2D R Snydman, B Sullivan, M Gill, et al.
Blood|November 15, 1991
Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytesG Vachino, J A Gelfand, M B Atkins, et al.
European Cytokine Network|April 22, 1999
Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapyE Vannier, A Kaser, M B Atkins, et al.
Pageof 11

Showing results (31-40 of 101) with videos related to

Sort By:
Pageof 11
Pathology and Immunopathology Research|January 1, 1988
Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cellsJ W Mier, F R Aronson, R P Numerof, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684B E Hillner, J M Kirkwood, M B Atkins, et al.
Critical Care Medicine|November 1, 1995
Effects of malignancy and interleukin-2 infusion on gut macromolecular permeabilityC M Ryan, M B Atkins, J W Mier, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1993
Possible myocardial toxicity associated with interleukin-4 therapyE G Trehu, J M Isner, J W Mier, et al.
Annals of Internal Medicine|April 15, 1993
Symptomatic exacerbation of Crohn disease after treatment with high-dose interleukin-2J A Sparano, L J Brandt, J P Dutcher, et al.
Diseases of the Colon and Rectum|April 1, 1994
Local excision of rectal carcinoma. Early results with combined chemoradiation therapy using 5-fluorouracil and leucovorinR A Graham, M B Atkins, D D Karp, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 15, 1987
Regulation of hepatic acute phase protein synthesis by products of interleukin 2 (IL 2)-stimulated human peripheral blood mononuclear cellsJ W Mier, C A Dinarello, M B Atkins, et al.
Annals of Internal Medicine|January 15, 1990
Nosocomial sepsis associated with interleukin-2D R Snydman, B Sullivan, M Gill, et al.
Blood|November 15, 1991
Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytesG Vachino, J A Gelfand, M B Atkins, et al.
European Cytokine Network|April 22, 1999
Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapyE Vannier, A Kaser, M B Atkins, et al.
Pageof 11